How to Help Your Patients Save Money on Entrectinib: A Provider's Guide to Savings Programs

At approximately $8,000 per 28-day supply with no generic available, Entrectinib (Rozlytrek) is one of the highest-cost oral oncology drugs in your patients' treatment plans. But with the right programs in place, many patients can significantly reduce their out-of-pocket burden — and your practice can play a critical role in connecting them to these resources. Here's a comprehensive provider guide to every savings program available for Rozlytrek in 2026.

Understanding the Cost Landscape

The cost of Rozlytrek creates three distinct patient populations, each requiring a different assistance approach:

Commercially insured patients: Often face high specialty tier copays or coinsurance. The Genentech co-pay program is typically the most impactful solution.

Medicare Part D patients: Cannot use manufacturer co-pay cards (federal anti-kickback regulations). Need independent foundation assistance or the Medicare Extra Help program.

Uninsured/underinsured patients: The Genentech Patient Foundation can provide the drug at no charge to qualifying patients.

Program 1: Genentech Oncology Co-pay Assistance Program

For commercially insured patients, the Genentech co-pay program offers the most powerful cost reduction. Key program details for Rozlytrek in 2026:

Patient benefit: $0 copay for eligible commercially insured patients; Genentech covers up to $25,000 per product per calendar year

Eligibility: Commercial insurance coverage for Rozlytrek, U.S. residency, not enrolled in a government-funded program (Medicare, Medicaid, Tricare, VA)

How to enroll: Contact Genentech Access Solutions at 877-436-3683 or use My Patient Solutions online portal. Enrollment should be initiated at prescription time, not after the first fill.

Calendar year reset: The $25,000 cap resets January 1 each year. Patients should be re-enrolled at year-start to avoid interruption.

Program 2: Genentech Patient Foundation

The Genentech Patient Foundation provides Rozlytrek at no charge to qualifying uninsured and underinsured patients. As a provider, you play a central role in the application process. To apply:

Contact Genentech Access Solutions at 877-436-3683

Submit the Prescriber Service Form and Patient Consent Form

Income and insurance documentation will be required for patient qualification

Program 3: Independent Co-pay Assistance Foundations (for Medicare Patients)

Federal regulations prohibit manufacturers from providing co-pay assistance to Medicare patients. However, independent nonprofit foundations — which receive general donations, not drug company funding for specific drugs — can legally provide assistance to Medicare patients. Genentech Access Solutions can refer your Medicare patients to:

CancerCare Co-Payment Assistance Foundation: cancercare.org/copayfoundation

Patient Access Network Foundation (PANF): panfoundation.org

HealthWell Foundation: healthwellfoundation.org

The Assistance Fund: tafconnects.org

Note: These foundations have limited funding and operate on a first-come, first-served basis. Refer patients early and consider having your social worker or case manager track open enrollment windows.

Program 4: Medicare Extra Help (Low Income Subsidy)

Medicare Part D patients with low incomes may qualify for the Extra Help program (also called Low Income Subsidy or LIS), which significantly reduces Part D premiums and specialty drug copays. Eligibility is based on income and resources. Patients can apply through the Social Security Administration (ssa.gov or 1-800-772-1213). Your social worker can assist with the application.

Practice-Level Best Practices for Managing Entrectinib Access

Identify insurance status before prescribing. Knowing upfront whether a patient has commercial or government insurance determines which assistance pathway to pursue.

Engage Genentech Access Solutions at prescribing. Don't wait for a cost-related crisis. Submitting the Prescriber Service Form and Patient Consent Form upfront triggers both the financial assistance enrollment and benefits investigation simultaneously.

Track the annual co-pay calendar. Commercial co-pay assistance resets on January 1. The $25,000 annual cap sounds large but can be reached in 3–4 months. Know where your patients are in their annual cycle.

Use a social worker for Medicare patients. Independent foundation applications are complex and have limited enrollment windows. A dedicated social worker can significantly improve success rates.

How medfinder Supports Patients Navigating Specialty Pharmacy Access

Even when financial assistance is in place, patients sometimes struggle to find a specialty pharmacy that can fill their Rozlytrek prescription. medfinder contacts pharmacies near the patient to find which ones can fill their prescription and texts them the results — reducing one more access barrier for your patients. For a patient-facing guide to savings, share our guide on how to save money on entrectinib with your patients.